GH Research PLC (NASDAQ:GHRS) Short Interest Up 21.1% in February

GH Research PLC (NASDAQ:GHRS - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 2,870,000 shares, an increase of 21.1% from the January 31st total of 2,370,000 shares. Currently, 7.9% of the shares of the company are sold short. Based on an average trading volume of 404,900 shares, the short-interest ratio is presently 7.1 days.

GH Research Trading Up 3.3 %

GHRS traded up $0.35 during midday trading on Monday, hitting $10.85. 218,460 shares of the company traded hands, compared to its average volume of 162,190. The business has a 50 day simple moving average of $10.80 and a two-hundred day simple moving average of $9.17. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50. The company has a market capitalization of $564.56 million, a price-to-earnings ratio of -13.76 and a beta of 0.94.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. Equities research analysts anticipate that GH Research will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

Several hedge funds and other institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. raised its stake in GH Research by 1.3% in the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company's stock valued at $44,734,000 after purchasing an additional 85,000 shares during the last quarter. Geode Capital Management LLC grew its stake in GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock valued at $508,000 after acquiring an additional 3,092 shares in the last quarter. Diadema Partners LP acquired a new stake in GH Research in the 4th quarter valued at about $711,000. Lynx1 Capital Management LP lifted its stake in GH Research by 15.8% in the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock worth $34,013,000 after purchasing an additional 663,100 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after purchasing an additional 8,641 shares during the last quarter. Hedge funds and other institutional investors own 56.90% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald initiated coverage on GH Research in a report on Thursday, February 13th. They issued an "overweight" rating and a $14.00 price objective for the company. Canaccord Genuity Group reduced their price target on GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, November 18th. Stifel Nicolaus raised their price objective on shares of GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Royal Bank of Canada assumed coverage on shares of GH Research in a research note on Friday. They issued an "outperform" rating and a $31.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of GH Research in a report on Monday, January 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $30.67.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).